By Colin Kellaher
Nektar Therapeutics on Thursday said it would regain full rights to rezpegaldesleukin from partner Eli Lilly & Co., which is ending a licensing agreement following the failure of the compound in a Phase 2 study in systemic lupus erythematosus.
San Francisco-based Nektar said it plans to work quickly to initiate a Phase 2b…
Read the full article here
